These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17374736)

  • 1. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
    Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
    Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
    Zheng B; Fuji RN; Elkins K; Yu SF; Fuh FK; Chuh J; Tan C; Hongo JA; Raab H; Kozak KR; Williams M; McDorman E; Eaton D; Ebens A; Polson AG
    Mol Cancer Ther; 2009 Oct; 8(10):2937-46. PubMed ID: 19808977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
    Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
    Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
    Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
    Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
    Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
    Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
    Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
    Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
    Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
    Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
    Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A
    Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
    Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
    Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
    Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
    Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
    Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Anti-CD22-
    Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
    Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
    Bourbon E; Salles G
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
    Chuprakov S; Ogunkoya AO; Barfield RM; Bauzon M; Hickle C; Kim YC; Yeo D; Zhang F; Rabuka D; Drake PM
    Bioconjug Chem; 2021 Apr; 32(4):746-754. PubMed ID: 33689309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.
    Ding S; Mao X; Cao Y; Wang N; Xu H; Zhou J
    Target Oncol; 2020 Jun; 15(3):365-375. PubMed ID: 32495161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.